Medigen Biotechnology Corp. (TPEX:3176)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
New Drugs and Vaccine Development		605.64M	389.62M	365.04M	3.28B	-
New Drugs and Vaccine Development Growth		55.44%	6.73%	-88.85%	-	-
Adjustments and Eliminations		-2.31M	-2.70M	-	-	-
Nucleic Acid Test		64.84M	61.73M	83.79M	98.34M	98.69M
Nucleic Acid Test Growth		5.05%	-26.33%	-14.80%	-0.36%	30.17%
Generic Drugs and Medical Aesthetic Products Department and Health Food Department		695.08M	709.07M	606.52M	536.53M	505.12M
Generic Drugs and Medical Aesthetic Products Department and Health Food Department Growth		-1.97%	16.91%	13.05%	6.22%	38.43%
Cell Therapy Department		9.45M	-	600.00K	11.98M	11.73M
Cell Therapy Department Growth		-	-	-94.99%	2.14%	-29.58%
Total		1.37B	1.16B	1.06B	3.92B	615.54M
Total Growth		18.57%	9.64%	-73.08%	537.17%	11.44%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan		1.34B	1.15B	1.01B	3.85B	543.23M
Taiwan Growth		17.25%	14.03%	-73.87%	608.39%	34.91%
China		4.44M	6.30M	39.59M	53.04M	40.86M
China Growth		-29.42%	-84.10%	-25.36%	29.81%	11.53%
Other		23.99M	4.96M	10.97M	20.79M	31.45M
Other Growth		383.88%	-54.82%	-47.22%	-33.90%	-72.50%
Total		1.37B	1.16B	1.06B	3.92B	615.54M
Total Growth		18.57%	9.64%	-73.08%	537.17%	11.44%

Source: S&P Global Market Intelligence.